Catalyst Pharmaceuticals (NASDAQ: CPRX) recently announced strong year-end results and followed that up with an announcement related to a stock repurchase program in March, which, when combined, should get that desired attention from investors. More than five years after securing the marketing rights for the drug Firdapse to treat adults suffering from Lambert-Eaton myasthenic syndrome (LEMS) -- a rare disease that impacts the signals sent between nerves and muscles, resulting in muscle weakness -- Catalyst submitted a new drug application and received approval from the U.S. Food and Drug Administration (FDA) in 2018. In its fourth-quarter earnings call for 2020, the company reported full-year revenue growth of 16% year over year, reaching $119.1 million.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting